SWOG clinical trial number
SWOG-8942

High Dose Etoposide, Cyclophosphamide and Either Fractionated Total Body Irradiation or Carmustine Combined with Autologous Bone Marrow Rescue for Refractory or Relapsed Non-Hodgkin's Lymphoma

Closed
Phase
Accrual
100%
Published
Abbreviated Title
High Dose Etoposide, Cyclophosphamide and Either Fractionated Total Body Irradiation or Carmustine Combined with Autologous Bone Marrow Rescue for Refractory or Relapsed Non-Hodgkin's Lymphoma
Activated
03/01/1990
Closed
12/15/1994

Research committees

Lymphoma

Publication Information Expand/Collapse

1998

Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: Value of augmented preparative regimens-A Southwest Oncology Group trial.

PJ Stiff;S Dahlberg;SJ Forman;AR McCall;SJ Horning;AP Nademanee;KG Blume;M LeBlanc;RI Fisher Journal of Clinical Oncology 16(1):48-55

1995

Autologous bone marrow transplantation (ABMT) for patients with diffuse non-Hodgkin's lymphoma: Value of augmented preparative regimens. A Southwest Oncology Group (SWOG) trial.

P Stiff;S Dahlberg;RI Fisher;A McCall;A Nademanee;SJ Forman;S Horning;K Blume ASCO 14:388(#1209)

Other Clinical Trials

SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase
SWOG Clinical Trial Number
S2114

A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
15%
Open
Phase